AU2022316939A1 - Methods for treating chronic spontaneous urticaria by administering an il-4r antagonist - Google Patents

Methods for treating chronic spontaneous urticaria by administering an il-4r antagonist Download PDF

Info

Publication number
AU2022316939A1
AU2022316939A1 AU2022316939A AU2022316939A AU2022316939A1 AU 2022316939 A1 AU2022316939 A1 AU 2022316939A1 AU 2022316939 A AU2022316939 A AU 2022316939A AU 2022316939 A AU2022316939 A AU 2022316939A AU 2022316939 A1 AU2022316939 A1 AU 2022316939A1
Authority
AU
Australia
Prior art keywords
subject
antibody
antigen
administered
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022316939A
Other languages
English (en)
Inventor
Nikhil AMIN
Elizabeth Laws
Leda MANNENT
Naimish Patel
Allen Radin
Heribert Staudinger
Aleksandra STJEPANOVIC
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Biotechnology SAS
Regeneron Pharmaceuticals Inc
Original Assignee
Sanofi Biotechnology SAS
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Biotechnology SAS, Regeneron Pharmaceuticals Inc filed Critical Sanofi Biotechnology SAS
Publication of AU2022316939A1 publication Critical patent/AU2022316939A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AU2022316939A 2021-07-26 2022-07-25 Methods for treating chronic spontaneous urticaria by administering an il-4r antagonist Pending AU2022316939A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202163225716P 2021-07-26 2021-07-26
US63/225,716 2021-07-26
US202163240734P 2021-09-03 2021-09-03
US63/240,734 2021-09-03
US202263313041P 2022-02-23 2022-02-23
US63/313,041 2022-02-23
EP22315049.1 2022-03-04
EP22315049 2022-03-04
US202263353654P 2022-06-20 2022-06-20
US63/353,654 2022-06-20
PCT/US2022/038185 WO2023009437A1 (en) 2021-07-26 2022-07-25 Methods for treating chronic spontaneous urticaria by administering an il-4r antagonist

Publications (1)

Publication Number Publication Date
AU2022316939A1 true AU2022316939A1 (en) 2024-03-07

Family

ID=82899210

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022316939A Pending AU2022316939A1 (en) 2021-07-26 2022-07-25 Methods for treating chronic spontaneous urticaria by administering an il-4r antagonist

Country Status (9)

Country Link
US (1) US20230146317A1 (https=)
EP (1) EP4377345A1 (https=)
JP (1) JP2024529434A (https=)
KR (1) KR20240037321A (https=)
AU (1) AU2022316939A1 (https=)
CA (1) CA3226781A1 (https=)
IL (1) IL310362A (https=)
MX (1) MX2024001189A (https=)
WO (1) WO2023009437A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9574004B2 (en) 2012-08-21 2017-02-21 Sanofi Biotechnology Methods for treating or preventing asthma by administering an IL-4R antagonist
BR112022000740A2 (pt) 2019-07-16 2022-07-05 Sanofi Biotechnology Métodos para tratamento ou prevenção de asma por administração de um antagonista de il-4r
WO2025088063A2 (en) * 2023-10-24 2025-05-01 Sanofi Systems and methods for monitoring a medicament dosing schedule
KR20250118250A (ko) * 2024-01-26 2025-08-06 연세대학교 산학협력단 식물에서 발현된 항-IL-4Rα 항체의 항원결합 단편 및 이의 용도

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US8178098B2 (en) 2001-04-03 2012-05-15 National Jewish Health Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−６受容体に対する高親和性抗体
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
MY149079A (en) 2006-10-02 2013-07-15 Regeneron Pharma High affinity human antibodies to human il-4 receptor
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
NZ609557A (en) 2010-10-06 2014-12-24 Regeneron Pharma Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
TWI633891B (zh) * 2013-06-04 2018-09-01 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑以治療過敏及增強過敏原－特異之免疫療法的方法
CN113372446A (zh) 2016-06-08 2021-09-10 苏州康乃德生物医药有限公司 用于结合白细胞介素4受体的抗体
KR102330596B1 (ko) 2018-11-09 2021-11-26 아주대학교산학협력단 인간 il-4 수용체 알파에 대한 고친화도 인간 항체 및 이의 용도
CA3132587A1 (en) * 2019-03-21 2020-09-24 Regeneron Pharmaceuticals, Inc. Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy

Also Published As

Publication number Publication date
EP4377345A1 (en) 2024-06-05
KR20240037321A (ko) 2024-03-21
MX2024001189A (es) 2024-02-27
CA3226781A1 (en) 2023-02-02
IL310362A (en) 2024-03-01
US20230146317A1 (en) 2023-05-11
JP2024529434A (ja) 2024-08-06
WO2023009437A1 (en) 2023-02-02

Similar Documents

Publication Publication Date Title
US20210322546A1 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
CN105263963B (zh) 伴pcsk9功能获得性突变的常染色体显性高胆固醇血症的治疗方法
US20230146317A1 (en) Methods for treating chronic spontaneous urticaria by administering an il-4r antagonist
US20190211090A1 (en) Method of treating osteoarthritis with an antibody to ngf
KR20240017117A (ko) 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법
KR20230082650A (ko) Il-4r 길항제를 투여하여 소아 대상체에서 천식을 치료하는 방법
TW202432598A (zh) 藉由投予il-4r拮抗劑治療手足皮膚炎的方法
US20230183362A1 (en) Methods for treating prurigo nodularis by administering an il-4r antagonist
CN115066272A (zh) Pcsk9抑制剂治疗纯合家族性高胆固醇血症的用途
WO2024047021A1 (en) Methods for treating chronic inducible cold urticaria by administering an il-4r antagonist
CN118139885A (zh) 通过施用il-4r拮抗剂以治疗慢性自发性荨麻疹的方法
WO2026059949A1 (en) Methods for treating chronic pruritus of unknown origin (cpuo) by administering an il-4r antagonist
HK40110800A (en) Methods for treating or preventing asthma by administering an il-4r antagonist
HK40070002A (en) Combination comprising an il-4r antagonist, a corticosteroid and a long-acting beta2-adrenergic agonist for treating asthma
HK40070002B (en) Combination comprising an il-4r antagonist, a corticosteroid and a long-acting beta2-adrenergic agonist for treating asthma
HK1231767B (en) Methods for treating or preventing asthma by administering an il-4r antagonist
EA041556B1 (ru) Ингибирующие антитела против pcsk9 для лечения пациентов с гиперлипидемией подвергающихся аферезу липопротеинов